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OBJECTIVES Our intent was to investigate the effect of the dihydropyridine calcium channel blocker
amlodipine on restenosis and clinical outcome in patients undergoing percutaneous translu-
minal coronary angioplasty (PTCA).
BACKGROUND Amlodipine has sustained vasodilatory effects and relieves coronary spasm, which may reduce
luminal loss and clinical complications after PTCA.
METHODS In a prospective, double-blind design, 635 patients were randomized to 10 mg of amlodipine
or placebo. Pretreatment with the study drug started two weeks before PTCA and continued
until four months after PTCA. The primary angiographic end point was loss in minimal
lumen diameter (MLD) from post-PTCA to follow-up, as assessed by quantitative coronary
angiography (QCA). Clinical end points were death, myocardial infarction, coronary artery
bypass graft surgery and repeat PTCA (major adverse clinical events).
RESULTS Angioplasty was performed in 585 patients (92.1%); 91 patients (15.6%) had coronary stents
implanted. Follow-up angiography suitable for QCA analysis was done in 236 patients in the
amlodipine group and 215 patients in the placebo group (per-protocol group). The mean loss
in MLD was 0.30 6 0.45 mm in the amlodipine group versus 0.29 6 0.49 mm in the placebo
group (p 5 0.84). The need for repeat PTCA was significantly lower in the amlodipine versus
the placebo group (10 [3.1%] vs. 23 patients [7.3%], p 5 0.02, relative risk ratio [RR]: 0.45,
95% confidence interval [CI]: 0.22 to 0.91), and the composite incidence of clinical events (30
[9.4%] vs. 46 patients (14.5%), p 5 0.049, RR: 0.65, CI: 0.43 to 0.99) within the four months
follow-up period (intention-to-treat analysis).
CONCLUSIONS Amlodipine therapy starting two weeks before PTCA did not reduce luminal loss, but the
incidence of repeat PTCA and the composite major adverse clinical events were significantly
reduced during the four-month follow-up period after PTCA with amlodipine as compared
with placebo. (J Am Coll Cardiol 2000;35:592–9) © 2000 by the American College of
Cardiology
Restenosis after percutaneous transluminal coronary angio-
plasty (PTCA) compromises the clinical advantage of the
method (1). Furthermore, although PTCA is accomplished
with a high success rate initially, the patients are still at risk
of cardiovascular complications and the need for repeat
revascularization (2–6). Intracoronary stent implantation
has reduced the incidence of restenosis and complications,
but it is an expensive alternative without complete inhibi-
tion of postinterventional luminal renarrowing (7,8). The
pathophysiology of restenosis has been extensively studied
and seems to be related to coronary spasm, recoil, platelet
aggregation, thrombus formation, intimal hyperplasia and
late vascular shrinkage (remodeling) (9–11). Several phar-
macologic trials have been done to study prevention of
restenosis, mostly without positive results (12). In five
previous restenosis trials with calcium channel blockers
(CCBs), no confident results were shown (13–17). These
studies had different study designs and important limita-
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tions, such as lack of quantitative coronary angiography
(QCA), adequate follow-up angiography and relative poor
sample size. A meta-analysis of five CCB trials has sug-
gested a reduction in the odds of angiographic restenosis in
the CCB-treated patients (18).
The dihydropyridine CCBs have been shown to inhibit
platelet aggregation in humans (19–21), especially in com-
bination with aspirin (22), and experimental data indicate
that they exert inhibitory effects on smooth muscle cell
proliferation (23). The vasodilatory effect of the dihydro-
pyridine CCB, amlodipine, is mainly in the peripheral and
coronary arteries and has been shown to be effective in
relieving coronary spasms (24–26). These actions seem
feasible in terms of reducing spasms and recoil induced by
angioplasty and promoting flow in the target vessel, which
may attenuate thrombus formation at the angioplasty site.
Furthermore, amlodipine has a gradual onset and long
duration of action (27). Pretreatment with amlodipine
before angioplasty, which has not been a part of the previous
CCB restenosis trials, may therefore be beneficial.
The Coronary AngioPlasty Amlodipine REStenosis
Study (CAPARES) was carried out to investigate the effect
of amlodipine on restenosis and clinical outcome in patients
undergoing PTCA.
METHODS
Study group. From 1992 to 1996, 635 patients suitable for
elective balloon angioplasty of one or more of the major
coronary arteries were included in the study from one
Norwegian (n 5 473) and four Canadian (n 5 162) centers.
Included were patients with stable angina pectoris and those
with de-novo lesions on native coronary arteries not totally
occluded at the initial diagnostic angiographic study. Ste-
nosis with a reference lumen diameter ,2 mm, visually
judged from the initial diagnostic angiogram, were not
included. The study was carried out in accordance with the
declaration of Helsinki and was approved by the local Ethics
Committees. Written, informed consent was obtained from
all patients.
Study protocol. CAPARES is a double-blind, placebo-
controlled study. Two weeks before PTCA, all patients
were randomized to receive either amlodipine or placebo
starting at 5 mg once daily the first week and then increasing
to 10 mg once daily. Clinical examinations and treatment
evaluation were performed two weeks and the day before
PTCA and two weeks and four months after PTCA as
follow-up. To achieve similar coronary vascular tone during
PTCA, 20 mg of nifedipine was administered (in a blinded
manner) orally twice before and once soon after PTCA to
patients randomized to receive placebo, and corresponding
placebo (nifedipine) tablets were given to the amlodipine-
treated patients. Nifedipine was administered as described
at follow-up angiography. All patients received aspirin.
Cholesterol-lowering drugs, angiotensin-converting en-
zyme inhibitors, diuretic agents, beta-blockers and noncar-
diovascular drugs were continued throughout the trial if
they were used before study entry. Nontest CCB treatment
was discontinued before study inclusion, but patients
stopped participating in the trial if discontinuation led to
crescendo angina or hypertension. Successful PTCA was
defined as satisfactory post-PTCA results (,50% diameter
stenosis as visually assessed by the operator) without major
in-hospital adverse cardiac events (death, myocardial infarc-
tion [MI], coronary artery bypass graft surgery [CABG] or
repeat PTCA). Stents were only implanted in bail-out
situations or because of an unsatisfactory post-PTCA result.
Patients with stents were not evaluated in the angiographic
per-protocol analysis.
Angioplasty procedure and follow-up angiography. Bal-
loon angioplasty was performed using the femoral approach
using an 8F guiding catheter. A bolus of 10,000 IU of
heparin was given intravenously before the procedure. Dur-
ing prolonged procedures (.1 h), an additional 5,000 IU of
heparin per hour was given. In case of angiographically
visible dissections, 10 IU of heparin per kg of body weight
per hour was given until the next morning. The same
angiographic views were obtained immediately before and
after PTCA and at follow-up. For study purposes, the
settings of the X-ray equipment (table height, field magni-
fication and projection angulations) were recorded for each
lesion, and an attempt was made to obtain two orthogonal
views, avoiding overlapping side branches and foreshorten-
ing of the lesions. The angiograms were analyzed using the
Cardiovascular Angiography Analysis System (CAAS II,
Pie Medical Imaging, Maastricht, the Netherlands) (28) by
a core laboratory (Norway), with the investigators blinded to
the treatment allocation. End-diastolic frames were selected
for edge-detection analysis, and the tip of the catheter was
used as a scaling device. Quantitative coronary angiography
was done as previously described (29).
End points. The primary angiographic end point was the
intrapatient mean loss in minimal lumen diameter (MLD)
(MLD after PTCA 2 MLD at follow-up). For patients
who had more than one lesion dilated, the average MLD of
all successfully dilated lesions was used for this analysis. The
secondary angiographic end point was the restenosis rate at
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAPARES 5 Coronary AngioPlasty Amlodipine
REStenosis Study
CCB 5 calcium channel blockers
CK 5 creatine kinase
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
QCA 5 quantitative coronary angiography
RR 5 relative risk
593JACC Vol. 35, No. 3, 2000 Jørgensen et al.
March 1, 2000:592–9 Results from CAPARES
follow-up, defined as a diameter stenosis $50% at
follow-up angiography in patients successfully dilated. The
clinical end points were death (all-cause), MI, CABG or
repeat PTCA performed before the scheduled follow-up
investigation. Myocardial infarction was determined by the
investigator at each site and was defined as chest pain
combined with either pathologic electrocardiographic
changes (new pathologic Q waves) or elevation of creatine
kinase (CK) or CK-MB fraction to more than twofold the
upper normal limit, or both. Cardiac enzymes (creatine
kinase) were checked before and after PTCA in all patients.
Interventions after successful PTCA (either CABG or
repeat PTCA) were clinically driven and only performed in
patients with escalating angina symptoms that led to a
premature angiographic examination. End points for every
patient were categorized into a composite end point, with
only one end point counting for each patient when more
than one event occurred. Clinical end points were primarily
evaluated in all randomized patients (intention-to-treat
analysis) and also in those who underwent PTCA while on
study medication. Patients with successful angioplasty with-
out stent implantation and who completed the study with
angiography suitable for QCA analysis were included in the
angiographic end point analysis (per-protocol analysis).
Statistical analysis. The number of patients in the study
was initially based on the concept of restenosis as a categoric
dichotomous end point. We initially calculated that 150
patients were required in each treatment group on the
assumption of a restenosis rate of 30% in the placebo group
and 15% in the amlodipine-treated group. After the study
was started, QCA became the “gold standard” for coronary
artery luminal measurements (30), and MLD, a continuous
variable, the main outcome variable in restenosis trials (31).
The protocol was adjusted and the number of patients
recalculated to be 233 in each treatment group (32).
Data are presented as the mean value 6 SD or number
(percent). The Student t test was used to compare contin-
uous variables, and for categoric variables, the chi-square
test or, when appropriate, the Fisher exact test was used,
applying a two-tailed alpha level of 0.05. Relative risk (RR)
for the clinical end points are given. Statistical analysis was
performed with use of StatView, version 5.0.
RESULTS
A total of 635 patients were randomized—318 received
amlodipine and 317 placebo. There were no statistical
differences in the baseline variables between the treatment
groups (Table 1). Ten patients in the amlodipine group
discontinued the study medication (owing to edema in five
patients, hypertension in one, nausea in one, abdominal
pain in one, unstable angina in one and delay of the planned
PTCA in one) and seven in the placebo group (owing to
unstable angina in four patients, hypertension in one,
urinary retention in one and nausea in one). Angioplasty
was performed in 585 patients (92.1%), and stents were
implanted in 91 patients (15.6%) (38 in the amlodipine
group and 53 in the placebo group). In total, 451 patients
(236 in the amlodipine group and 215 in the placebo group)
had follow-up angiography suitable for QCA analysis (per-
protocol analysis). There was no difference in baseline
clinical and angiographic variables between those adhering
to the protocol versus those not adhering to it, except that
those adhering were younger (two years, p 5 0.01) and
more of them (11.2%, p 5 0.01) had single-vessel disease.
The patient flowchart is shown in Table 2. The median time
to follow-up angiography was 132 days (range 21 to 167) in
the amlodipine group and 131 days (range 27 to 179) in the
placebo group (p 5 NS).
Angiographic results. Angiographic baseline characteris-
tics (per-protocol analysis) did not differ significantly be-
tween the two groups (Table 3). There were no significant
differences in reference diameter or MLD immediately
before and after angioplasty or at follow-up between the two
groups (Table 4). Both groups achieved the same gain in
MLD (from pre-PTCA to post-PTCA), and there was no
significant difference in loss of MLD (from post-PTCA to
follow-up) between the two groups (mean difference
0.01 mm, 95% confidence interval [CI] 20.08 to 0.10 mm).
The cumulative distribution curves for MLD before and
Table 1. Clinical Baseline Variables of all Randomized Patients
(Intention-to-Treat Analysis)
Amlodipine
Group
(n 5 318)
Placebo
Group
(n 5 317)
Age (year) 56.5 6 9.0 56.1 6 8.8
Male gender 267 (84.0%) 255 (80.4%)
Smoker 75 (23.6%) 71 (22.4%)
Diabetes 22 (6.9%) 28 (8.8%)
Hypertension 87 (27.4%) 78 (24.6%)
Previous MI 125 (39.3%) 125 (39.4%)
Canadian Cardiovascular
Society Classification
I 62 (19.5%) 60 (18.9%)
II 162 (52.6%) 155 (50.8%)
III, IV 94 (30.5%) 102 (33.4%)
Duration of angina
(months)
24.4 6 39.9 25.9 6 45.4
Concomitant medications
Beta-blocker 272 (85.5%) 269 (84.9%)
Nitrate 157 (49.4%) 148 (46.7%)
Statin 84 (26.4%) 80 (25.2%)
Aspirin 272 (85.5%) 273 (86.1%)
Number of vessels .50%
obstructed
One 185 (58.2%) 176 (55.5%)
Two 106 (33.3%) 115 (36.3%)
Three 27 (8.5%) 26 (8.2%)
LVEF 71.0 6 12.2% 72.8 6 10.4%
Data are presented as mean value 6 SD or number (%) of patients.
LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction.
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after PTCA and at follow-up are shown in Figure 1. The
restenosis rates (per patient) were 28.1% in the amlodipine
group and 28.4% in the placebo group (p 5 0.95). Analyzed
per vessel, the restenosis rates were 29.7% in the amlodipine
group and 29.9% in the placebo group (p 5 0.97).
Clinical results. There was a 4.2% (p 5 0.02) absolute
reduction in the clinically driven need for repeat PTCA
before the scheduled follow-up angiography, and a 5.1%
(p 5 0.049) reduction in the incidence of major adverse
clinical events in the amlodipine group as compared with
the placebo group (intention-to-treat analysis). The out-
come for all patients randomized and for the patients who
underwent PTCA while on the study drug are shown in
Table 5. One patient in the placebo group died of ventric-
ular fibrillation 6 h after PTCA, and one patient without
PTCA also in the placebo group, had a cardiac death three
months after study inclusion. One patient in the amlodipine
group died of metastatic pancreatic cancer that was not
diagnosed before study inclusion. Three patients in the
amlodipine group had an MI after discontinuation of the
study drug. Five patients in the amlodipine group and nine
in the placebo group had a MI in-hospital after PTCA, and
two patients in the placebo group had an MI after hospital
discharge. Nine patients in the amlodipine group and five in
the placebo group were referred for elective CABG without
the scheduled PTCA being performed. Urgent CABG was
performed in the hospital in three patients in the amlodip-
ine group and seven in the placebo group. Two patients in
the amlodipine group and six in the placebo group under-
went CABG after hospital discharge. One patient in the
amlodipine group who discontinued the study medication
before the scheduled PTCA had a repeat PTCA. Five
patients in the placebo group underwent urgent repeat
PTCA in the hospital. Nine patients the amlodipine group
and 18 in the placebo group underwent repeat PTCA after
hospital discharge, before follow-up angiography.
DISCUSSION
In the present study, amlodipine starting two weeks before
PTCA did not prevent luminal loss or restenosis as assessed
by angiography four months after successful PTCA. In the
amlodipine group, the need for target vessel repeat PTCA
Table 2. Patient Flow From Time of Randomization to Follow-Up in the Amlodipine and
Placebo Groups
Amlodipine
Group
Placebo
Group
p
Value
Patients randomized (intention-to-treat analysis) n 5 318 n 5 317 —
Medication stopped before PTCA 6 5 1.0
Denied PTCA 2 3 0.69
No stenosis 1 2 0.62
Elective CABG instead of PTCA 6 5 1.0
PTCA not technically feasible 12 8 0.37
PTCA performed n 5 291 n 5 294 0.56
Stents implanted 38 53 0.09
Unsuccessful PTCA without complications 1 1 1.0
In-hospital complications 8 16 0.09
Out-of-hospital complications (no repeat
angiography)
2 0 —
Medication stopped after PTCA 4 2 0.69
Denied follow-up angiography 3 4 0.72
Considered high risk angiography 0 2 —
QCA not technically possible 3 7 0.22
Per-protocol angiographic analysis n 5 236 n 5 215 0.08
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous transluminal coronary angioplasty; QCA 5 quantitative
coronary angiography.
Table 3. Angiographic Variables of the Per-Protocol
Analysis Group
Amlodipine
Group
(n 5 236)
Placebo
Group
(n 5 215)
Vessels dilated n 5 268 n 5 237
LAD 127 (53.8%) 107 (47.7%)
LCx 43 (18.2%) 46 (21.4%)
RCA 86 (36.4%) 72 (33.5%)
Diagonal branch 4 (1.7%) 6 (2.8%)
Left oblique marginal 5 (2.1%) 4 (1.9%)
Intermediate 3 (1.3%) 2 (0.9%)
Dilation sites 281 244
Vessels dilated per patient 1.13 1.10
Occluded vessels before
PTCA
19 (6.8%) 20 (8.2%)
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right
coronary artery.
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and the composite incidence of major adverse clinical events
were significantly lower, both in the intention-to-treat
analysis and by analysis of those patients who underwent
PTCA (treatment group), but no difference in the incidence
of death and MI was seen.
Lack of effect on angiographic variables. A lack of effect
of amlodipine on MLD and restenosis is in agreement with
previous CCB restenosis trials (13–17,33). In these trials
three different types of CCBs were used and study designs
varied—coronary artery measurements were mostly without
QCA, a small number of patients were enrolled and the
proportions of patients without angiographic follow-up
were relatively high. In the present study, a sufficient
number of patients were enrolled, angiographic follow-up
was carried out in 91% of patients and QCA was used.
Thus, this trial is presently the largest CCB restenosis trial
to date.
In the present study, follow-up angiography was done
four months after PTCA based on the studies by Serruys et
al. (34) and Nobuyoshi et al. (35), which demonstrated that
luminal renarrowing is a time-related phenomenon devel-
oping during the first four months after angioplasty. Al-
though repeat angiography is usually done six months after
PTCA in most restenosis trials, it is unlikely that further
luminal changes would occur from the fourth to the sixth
month. The present angiographic results are nearly identical
to those of Rensing et al. (31), who examined 1,445
successfully dilated lesions with QCA before and immedi-
ately after balloon angioplasty and at six-month follow-up.
The mean values 6 SD of the reference diameter of the
target lesions in both treatment groups were similar to those
in the study by Rensing et al. (31), in which nitroglycerin
was used to control vascular tone. Thus, adequate vasodila-
tion was provided by the use of amlodipine or nifedipine at
angioplasty and repeat angiography.
The development of restenosis has mainly been explained
by thrombus formation, smooth muscle cell proliferation
and extracellular matrix formation resulting in intimal
hyperplasia (36). Elastic recoil and vascular spasm have also
been proposed as early factors in the complex chain of events
(37). Previous pharmacologic trials on restenosis prevention
have been aimed at interfering with thrombus formation
and intimal hyperplasia, but the results have mostly been
negative (12). The lack of effect of pharmacologic agents
may be explained by additional factors leading to restenosis.
Intravascular ultrasound examination, which delineates the
vessel wall structures (38), suggests that shrinkage of the
Figure 1. Cumulative distribution curves for MLD in the amlo-
dipine (n 5 236) and placebo (n 5 215) groups (per-protocol
group) before and immediately after PTCA and at four-month
follow-up after PTCA.
Table 4. Coronary Quantitative Angiographic Analysis in the Per-Protocol Analysis Group
Amlodipine Group
(n 5 236)
Placebo Group
(n 5 215)
p
Value
Reference diameter (mm)
Before angioplasty 2.59 6 0.51 2.62 6 0.52 0.45
After angioplasty 2.62 6 0.47 2.64 6 0.48 0.71
At follow-up 2.56 6 0.46 2.62 6 0.51 0.18
Obstruction diameter, MLD (mm)
Before angioplasty 0.92 6 0.35 0.92 6 0.40 0.95
After angioplasty 1.82 6 0.37 1.79 6 0.34 0.40
At follow-up 1.52 6 0.57 1.50 6 0.59 0.71
Diameter stenosis (percent)
Before angioplasty 64.7 6 12.6 64.8 6 13.5 0.89
After angioplasty 30.4 6 9.4 31.8 6 9.2 0.12
At follow-up 41.3 6 17.5 42.9 6 19.3 0.34
Gain (mm) 0.90 6 0.40 0.87 6 0.42 0.42
Loss (mm) 0.30 6 0.45 0.29 6 0.49 0.84
Data are presented as the mean value 6 SD.
MLD 5 minimal lumen diameter.
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vessel wall, with only slight intimal thickening, is the
predominant cause of postinterventional luminal loss (re-
modeling) (9,10,39). Pharmacologic agents administered in
therapeutic doses seem to be inadequate to limit the
shrinkage of the vessel wall at the lesion site, and this may
explain the failure of restenosis reduction in this study and
most other studies.
Clinical outcome. Clinical events were included in only
one of the previous CCB restenosis trials, and in this trial
diltiazem did not reduce cardiac events after PTCA (17). In
the present study, the incidence of repeat PTCA and the
composite major clinical events were reduced, despite the
apparent lack of effect on angiographic variables. In the
Prospective Randomized Evaluation of the Vascular Effects
of Norvasc Trial (PREVENT) (40), amlodipine failed to
reduce progression of coronary atherosclerosis as assessed by
QCA, but major vascular procedures were significantly
reduced in the amlodipine group.
The discrepancy between the angiographic and clinical
results may be attributable to the limited angiographic area
under investigation—that is, the target lesion only. Vaso-
constriction and spasms may facilitate occlusion of the
dilated artery and thus lead to infarction or the need for
urgent revascularization. Amlodipine has been shown to
induce sustained relaxation of coronary arteries, which
augments the total myocardial blood flow without reflex
tachycardia (26,41,42). Enhancement of the subendocardial
and collateral blood flow may also reduce the myocardium
in jeopardy. In animals subjected to coronary artery occlu-
sion, amlodipine decreased the size of the ischemic regions
and improved myocardial segmental function of the reper-
fused region, and amlodipine has also been shown to reduce
myocardial oxygen consumption, coronary vascular resis-
tance and infarct size (43,44). Thus, the anti-ischemic
effects of amlodipine (45–47) most probably reflect the
reduced need for target vessel revascularization before the
scheduled repeat angiography.
Study limitations. The fact that intracoronary nitroglyc-
erin was not given routinely to all patients before angiog-
raphy deviates from standard study design when assessing
angiographic end points (48), although the CCBs given
provided satisfactory vasomotor control.
The clinical events were observed from a study population
in which the power and sample size calculations were based
on a 30% reduction in mean loss of MLD, that is angio-
graphic end points. Taking into consideration the relative
short time to follow-up, it is possible that the rates of events
could have been different if six months of follow-up had
been used instead of four months. The effect of amlodipine
should be tested in another prospective, randomized study
with a longer follow-up time, designed and powered for
evaluating clinical end points in patients after successful
coronary angioplasty.
Conclusions. In the present study, amlodipine treatment
starting two weeks before angioplasty and continuing for
four months after angioplasty did not reduce restenosis after
PTCA. The incidence of composite major adverse clinical
events was significantly reduced in the patients treated with
amlodipine, but the difference was mainly due to a reduction
in the number of repeat PTCAs. The need for repeat
PTCA was driven by ischemic symptoms, attributed to the
anti-ischemic effects by amlodipine. The clinical results
should be confirmed in a larger trial with longer follow-up.
Table 5. Clinical End Points in All Randomized Patients (Intention-to-Treat) and All Patients Who Underwent the Scheduled
Percutaneous Transluminal Coronary Angioplasty
Events*
All Randomized Patients
Amlodipine Group
(n 5 318)
Placebo Group
(n 5 317) p Value
Relative Risk
(95% CI)
Death 1 (0.3%) 2 (0.6%) 0.62 0.60 (0.08–4.50)
MI 8 (2.5%) 11 (3.5%) 0.49 0.73 (0.31–1.76)
CABG 14 (4.4%) 18 (5.7%) 0.46 0.78 (0.40–1.52)
Repeat PTCA 10 (3.1%) 23 (7.3%) 0.02 0.45 (0.22–0.91)
Composite end points 30 (9.4%) 46 (14.5%) 0.049 0.65 (0.43–0.99)
Patients Treated With PTCA While on Study Drug
Amlodipine Group
(n 5 291)
Placebo Group
(n 5 294) p Value
Relative Risk
(95% CI)
Death 1 (0.3%) 1 (0.3%) 0.99 —
MI 5 (1.7%) 11 (3.7%) 0.13 0.48 (0.18–1.31)
CABG 5 (1.7%) 13 (4.4%) 0.058 0.41 (0.15–1.09)
Repeat PTCA 9 (3.1%) 23 (7.8%) 0.011 0.41 (0.20–0.85)
Composite end points 20 (6.9%) 40 (13.6%) 0.007 0.51 (0.31–0.85)
*All events are included, except for the composite end points, in which only the first end point occurring is counted. Data are presented as the number (%) of patients.
MI 5 myocardial infarction; other abbreviations as in Table 2.
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APPENDIX
Participating Centers and Principal Investigators in
CAPARES
Bjørn Jørgensen, Rikshospitalet, Oslo, Norway (Primary
investigator and core angiographic laboratory); James Han-
sen, University of Calgary, Foothills Hospital, Canada; John
Webb, St. Paul Hospital, Vancouver, Canada; Christopher
Buller, Cardiology Research, Vancouver Hospital, Canada;
and Gilles Goulet, Hospital Saint-Luc, Montreal, Canada.
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